BIOMAT Database Logo BIOMAT Database Logo

Loxapine yields amoxapine. 1984

M A Badway, and J E Dugas

UI MeSH Term Description Entries
D008152 Loxapine An antipsychotic agent used in SCHIZOPHRENIA. Loxapinsuccinate,Oxilapine,2-Chloro-11-(4-methyl-1-piperazinyl)-dibenz(b,f)(1,4)oxazepine,CL-71,563,Cloxazepine,Loxapine Hydrochloride,Loxapine Monohydrochloride,Loxapine Succinate,Loxipine Maleate,Loxipine Succinate,Loxitane,CL 71,563,CL71,563,Hydrochloride, Loxapine,Maleate, Loxipine,Succinate, Loxapine
D003989 Dibenzoxazepines
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000657 Amoxapine The N-demethylated derivative of the antipsychotic agent LOXAPINE that works by blocking the reuptake of norepinephrine, serotonin, or both; it also blocks dopamine receptors. Amoxapine is used for the treatment of depression. 2-Chloro-11-(1-piperazinyl)dibenz(b,f)(1,4)oxazepine,Asendin,Asendis,CL-67,772,Demolox,Desmethylloxapine,Défanyl,CL 67,772,CL67,772
D001711 Biotransformation The chemical alteration of an exogenous substance by or in a biological system. The alteration may inactivate the compound or it may result in the production of an active metabolite of an inactive parent compound. The alterations may be divided into METABOLIC DETOXICATION, PHASE I and METABOLIC DETOXICATION, PHASE II.

Related Publications

M A Badway, and J E Dugas
Nonketotic hyperglycemia associated with loxapine and amoxapine: case report.
September 1983, The Journal of clinical psychiatry,
M A Badway, and J E Dugas
Validation of HPLC-MS/MS methods for analysis of loxapine, amoxapine, 7-OH-loxapine, 8-OH-loxapine and loxapine N-oxide in human plasma.
December 2010, Bioanalysis,
M A Badway, and J E Dugas
Prolactin stimulating effects of amoxapine and loxapine in psychiatric patients.
January 1982, Psychopharmacology,
M A Badway, and J E Dugas
GLC analysis of loxapine, amoxapine, and their metabolites in serum and urine.
February 1979, Journal of pharmaceutical sciences,
M A Badway, and J E Dugas
Simultaneous quantification of loxapine, loxapine N-oxide, amoxapine, 8-hydroxyloxapine and 7-hydroxyloxapine in human plasma using LC-MS/MS.
March 2017, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences,
M A Badway, and J E Dugas
Effect of loxapine and amoxapine on oxidative metabolism of rat brain "in vitro".
August 1985, Archivos de farmacologia y toxicologia,
M A Badway, and J E Dugas
Ligand binding and platelet uptake studies of loxapine, amoxapine and their 8-hydroxylated derivatives.
June 1982, Journal of affective disorders,
M A Badway, and J E Dugas
Concurrent high-performance liquid chromatographic measurement of loxapine and amoxapine and of their hydroxylated metabolites in plasma.
June 1998, Therapeutic drug monitoring,
M A Badway, and J E Dugas
Simultaneous quantitation of loxapine, amoxapine and their 7- and 8-hydroxy metabolites in plasma by high-performance liquid chromatography.
March 1991, Journal of chromatography,
M A Badway, and J E Dugas
[Comparison of the affinities of amoxapine and loxapine for various receptors in rat brain and the receptor down-regulation after chronic administration].
January 1990, Yao xue xue bao = Acta pharmaceutica Sinica,
Copied contents to your clipboard!